Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Syros Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SYRS
Nasdaq
8731
https://syros.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript
- Mar 28th, 2024 2:06 pm
Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
- Mar 28th, 2024 10:47 am
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
- Mar 27th, 2024 11:30 am
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
- Mar 25th, 2024 11:00 am
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
- Mar 20th, 2024 11:00 am
Syros to Participate in TD Cowen 44th Annual Health Care Conference
- Feb 27th, 2024 12:00 pm
Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year
- Feb 27th, 2024 10:15 am
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
- Jan 31st, 2024 9:00 pm
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
- Jan 19th, 2024 3:43 pm
Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice
- Jan 18th, 2024 5:00 pm
Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why
- Jan 17th, 2024 1:50 pm
What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
- Jan 16th, 2024 5:00 pm
Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
- Jan 16th, 2024 2:55 pm
Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
- Jan 11th, 2024 1:48 pm
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
- Jan 8th, 2024 12:00 pm
Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals
- Jan 4th, 2024 4:03 am
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Dec 19th, 2023 12:27 pm
individual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last week
- Dec 13th, 2023 11:22 am
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
- Dec 7th, 2023 2:44 pm
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
- Dec 6th, 2023 12:00 pm
Scroll